Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Jubilant Pharmova Limited ( (IN:JUBLPHARMA) ) has issued an update.
Jubilant Pharmova Limited has announced that its wholly owned subsidiary, Jubilant Biosys Limited, received an Adjudication Order from the Deputy Commissioner of Commercial Taxes, Mysuru, concerning a demand for GST, interest, and penalty for the financial year 2021-2022. The company plans to file an appeal against the order, arguing that it is legally incorrect and expects no financial or operational impact from the order.
More about Jubilant Pharmova Limited
Jubilant Pharmova Limited operates in the pharmaceutical industry, focusing on the development and manufacturing of a wide range of pharmaceutical and life sciences products. The company is involved in providing innovative solutions and services to its clients, with a market focus on healthcare and life sciences sectors.
Average Trading Volume: 7,946
Technical Sentiment Signal: Buy
Current Market Cap: 170.3B INR
See more data about JUBLPHARMA stock on TipRanks’ Stock Analysis page.